Your browser is no longer supported. Please, upgrade your browser.
Settings
AFMD Affimed N.V. daily Stock Chart
AFMD [NASD]
Affimed N.V.
Index- P/E- EPS (ttm)-0.76 Insider Own5.78% Shs Outstand69.64M Perf Week-12.00%
Market Cap153.21M Forward P/E- EPS next Y-0.75 Insider Trans0.00% Shs Float61.92M Perf Month8.64%
Income-35.90M PEG- EPS next Q-0.19 Inst Own58.20% Short Float0.54% Perf Quarter3.53%
Sales2.50M P/S61.28 EPS this Y28.90% Inst Trans32.69% Short Ratio0.82 Perf Half Y4.76%
Book/sh1.16 P/B1.90 EPS next Y-1.30% ROA-58.90% Target Price7.42 Perf Year-6.38%
Cash/sh- P/C- EPS next 5Y- ROE-76.80% 52W Range1.15 - 2.85 Perf YTD69.23%
Dividend- P/FCF- EPS past 5Y-1.40% ROI-70.30% 52W High-22.81% Beta2.40
Dividend %- Quick Ratio6.60 Sales past 5Y11.40% Gross Margin- 52W Low91.30% ATR0.13
Employees61 Current Ratio6.60 Sales Q/Q25.00% Oper. Margin- RSI (14)47.77 Volatility5.77% 6.07%
OptionableYes Debt/Eq0.12 EPS Q/Q21.10% Profit Margin- Rel Volume1.81 Prev Close2.45
ShortableYes LT Debt/Eq0.06 EarningsMay 15 BMO Payout- Avg Volume406.68K Price2.20
Recom2.00 SMA20-1.73% SMA502.78% SMA20011.07% Volume734,292 Change-10.20%
Jul-14-17Initiated SunTrust Buy $7
Aug-12-16Downgrade Leerink Partners Outperform → Mkt Perform
May-19-16Downgrade Leerink Partners Outperform → Mkt Perform
Dec-10-15Initiated Laidlaw Buy $15
Dec-04-15Initiated Wells Fargo Outperform
Sep-09-15Initiated Jefferies Hold
Aug-06-15Reiterated Oppenheimer Outperform $14 → $19
Jun-22-15Reiterated Jefferies Buy $12 → $16
May-24-18 08:32AM  Edited Transcript of AFMD earnings conference call or presentation 15-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-18-18 04:01PM  Affimed Announces Annual General Meeting of Shareholders GlobeNewswire
May-15-18 09:55AM  Does Affimed NV. (NASDAQ:AFMD) Fall With The Market? Simply Wall St.
07:45AM  Affimed Reports Financial Results for First Quarter 2018 GlobeNewswire
06:45AM  Affimed N.V. to Host Earnings Call ACCESSWIRE
May-08-18 05:00AM  Affimed Announces First Quarter 2018 Financial Results and Corporate Update Conference Call GlobeNewswire
May-03-18 05:00AM  Affimed to Present at Deutsche Bank's 43rd Annual Health Care Conference GlobeNewswire
05:00AM  Affimed Introduces ROCK(TM) Platform for Tailored Immune Cell Engagers GlobeNewswire
Apr-19-18 07:40AM  Blog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugens BAY 1905254 Efficacy in Cancer Immunotherapy ACCESSWIRE
Apr-16-18 02:01PM  Affimed Presents Poster at AACR Highlighting Progress Toward Novel EGFR-targeting Therapy GlobeNewswire
Mar-20-18 09:16PM  Edited Transcript of AFMD earnings conference call or presentation 20-Mar-18 12:30pm GMT Thomson Reuters StreetEvents
07:31AM  Affimed Reports Financial Results for Fourth Quarter and Year End 2017 GlobeNewswire
06:30AM  Affimed N.V. to Host Earnings Call ACCESSWIRE
Mar-19-18 05:58PM  Has Affimed NV. (NASDAQ:AFMD) Improved Earnings Growth In Recent Times? Simply Wall St. -6.98%
08:49AM  Why Earnings Season Could Be Great for Affimed (AFMD) Zacks
06:01AM  Affimed Appoints Dr. Leila Alland as Chief Medical Officer GlobeNewswire
Mar-15-18 04:01AM  Affimed to Present Data on AFM24 at AACR Annual Meeting 2018 GlobeNewswire
Mar-13-18 06:00AM  Affimed Announces Fourth Quarter and Year End 2017 Financial Results and Corporate Update Conference Call GlobeNewswire
Mar-12-18 03:10PM  Affimed NV. (NASDAQ:AFMD): When Will It Breakeven? Simply Wall St.
Mar-08-18 05:00AM  Affimed to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Feb-22-18 03:13PM  Breaking Down Affimed NV.s (NASDAQ:AFMD) Ownership Structure Simply Wall St.
Feb-15-18 04:02PM  Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares GlobeNewswire
01:39PM  Is Affimed NV.s (NASDAQ:AFMD) CEO Pay Justified? Simply Wall St.
Feb-13-18 03:01AM  Affimed Announces Pricing of Public Offering of Common Stock GlobeNewswire -16.33%
Feb-12-18 04:04PM  Affimed Announces Proposed Public Offering of Common Stock GlobeNewswire
11:02AM  Best High Growth NasdaqCM Stocks This Week Simply Wall St.
Feb-05-18 10:15AM  Affimed, Alnylam Are End Of The Week Movers In Biotech Market Exclusive +41.33%
Feb-01-18 08:30AM  Affimed Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas GlobeNewswire +39.62%
Jan-29-18 03:32PM  Should You Have Affimed NVs (NASDAQ:AFMD) In Your Portfolio? Simply Wall St.
Jan-10-18 08:42AM  Affimed NV (NASDAQ:AFMD): Immense Growth Potential? Simply Wall St.
Dec-28-17 11:02AM  Growth Stocks Investors Love Simply Wall St.
Dec-15-17 09:55AM  Did Affimed NVs (NASDAQ:AFMD) Recent Earnings Growth Beat The Trend? Simply Wall St.
Dec-11-17 05:01AM  Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH GlobeNewswire -23.08%
Nov-28-17 08:00AM  Affirmed, Data Due in December, Potential Catalysts, Clinical Highlights ACCESSWIRE -5.13%
Nov-27-17 11:02AM  Best Growth Stock Picks Simply Wall St. -7.14%
Nov-15-17 03:01AM  Affimed to Present at the Jefferies 2017 London Healthcare Conference GlobeNewswire -13.58%
Nov-10-17 02:55PM  What Does Affimed NVs (AFMD) Share Price Indicate? Simply Wall St.
Nov-08-17 02:44PM  Affimed NV :AFMD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017 Capital Cube
Nov-07-17 04:31PM  Edited Transcript of AFMD earnings conference call or presentation 7-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
07:30AM  Affimed Reports Financial Results for Third Quarter 2017 GlobeNewswire
Nov-02-17 05:59AM  Affimed to Present at the 26th Annual Credit Suisse Healthcare Conference GlobeNewswire
Nov-01-17 09:18AM  Affimed to Present Clinical and Preclinical Data on Immune Cell Engagers at ASH GlobeNewswire
Oct-30-17 06:01AM  Affimed Announces Third Quarter 2017 Financial Results and Corporate Update Conference Call GlobeNewswire
Oct-27-17 03:11PM  Are Affimed NVs (AFMD) Interest Costs Too High? Simply Wall St.
Oct-25-17 10:12AM  AbCheck and Molecular Templates Announce Collaboration to Discover Therapeutic Oncology Leads GlobeNewswire
Sep-22-17 08:02AM  Affimed to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology GlobeNewswire
Sep-13-17 04:07PM  What Is Affimed NVs (AFMD) Share Price Doing? Simply Wall St. +7.14%
05:02AM  Affimed Appoints Dr. Wolfgang Fischer as Chief Operating Officer GlobeNewswire
Sep-06-17 08:40AM  Affimed NV :AFMD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 6, 2017 Capital Cube
Sep-04-17 05:01AM  Affimed to Present at the 2017 Wells Fargo Healthcare Conference - Boston GlobeNewswire
Aug-12-17 06:40AM  Edited Transcript of AFMD earnings conference call or presentation 1-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-01-17 07:31AM  Affimed Reports Financial Results for Second Quarter 2017 GlobeNewswire
Jul-25-17 05:01AM  Affimed Announces Second Quarter 2017 Financial Results and Corporate Update Conference Call GlobeNewswire
Jul-10-17 08:15AM  Affimed (AFMD) Looks Good: Stock Moves Up 8.7% in Session Zacks
Jun-27-17 05:01AM  Affimed Presents Preclinical Data on AFM24 and AFM26 at EACR-AACR-SIC 2017 GlobeNewswire
Jun-06-17 05:01AM  Affimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017 GlobeNewswire
May-30-17 05:00AM  Affimed to Present at the Jefferies 2017 Global Healthcare Conference - New York GlobeNewswire
May-22-17 09:46AM  Affimed Announces Annual General Meeting of Shareholders GlobeNewswire -6.00%
May-17-17 05:09PM  Affimed to Present Immune Cell Engager Data at ASCO Annual Meeting and EACR-AACR-SIC Special Conference GlobeNewswire
07:30AM  Affimed Reports Financial Results for First Quarter 2017 GlobeNewswire
May-10-17 05:01AM  Affimed Announces First Quarter 2017 Financial Results and Corporate Update Conference Call GlobeNewswire
Apr-06-17 09:14AM  Affimed NV :AFMD-US: Earnings Analysis: Q4, 2016 By the Numbers : April 6, 2017 Capital Cube
Apr-05-17 02:01PM  Affimed Presents Data on Immune Cell Engager Pipeline at the AACR Annual Meeting 2017 GlobeNewswire
Mar-30-17 07:31AM  Affimed Reports Financial Results for Fourth Quarter and Year End 2016 GlobeNewswire
07:07AM  Q4 2016 Affimed NV Earnings Release - Time Not Supplied
Mar-23-17 06:01AM  Affimed Announces Fourth Quarter and Year End 2016 Financial Results and Corporate Update Conference Call GlobeNewswire +10.64%
Mar-20-17 08:35AM  Are Options Traders Betting on a Big Move in Affimed (AFMD) Stock? Zacks
Mar-17-17 08:35AM  Innocoll Holdings (INNL) Shows Strength: Stock Up 36.6%
Mar-15-17 06:27AM  Affimed to Present at the Oppenheimer 27th Annual Healthcare Conference - New York GlobeNewswire
Mar-14-17 10:13AM  Affimed (AFMD) Shares March Higher, Can It Continue? Zacks
06:01AM  Affimed to Present at the Oppenheimer 27th Annual Healthcare Conference - New York GlobeNewswire
Mar-01-17 05:19PM  Affimed to Present Data on Immune Cell Engagers at the AACR Annual Meeting 2017 GlobeNewswire
Feb-28-17 05:01AM  Affimed to Present at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-15-17 07:46AM  Can The Uptrend Continue for Affimed N.V. (AFMD)? Zacks
Feb-08-17 05:01AM  Affimed to Present at the Leerink Partners 6th Annual Global Healthcare Conference GlobeNewswire
Feb-06-17 08:20AM  Affimed (AFMD) Shows Strength: Stock Moves 8.1% Higher Zacks
08:20AM  Affimed (AFMD) Shows Strength: Stock Moves 8.1% Higher
Jan-31-17 05:00AM  First Clinical Milestone Achieved in Collaboration between AbCheck and Lilly GlobeNewswire
Jan-25-17 04:01PM  Affimed Announces Closing of Public Offering of Common Stock GlobeNewswire
Jan-20-17 09:13AM  Affimed Announces Pricing of Public Offering of Common Stock GlobeNewswire -16.28%
Jan-19-17 04:04PM  Affimed Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-11-17 08:53AM  Affimed Provides Update on NK-Cell Immuno-Oncology Platform GlobeNewswire
Jan-05-17 08:15AM  Can The Uptrend Continue for Affimed N.V. (AFMD)?
08:15AM  Blog Coverage Affimed Join Hands with MD Anderson Cancer Center for Clinical Immuno-Oncology Development Collaboration Accesswire
Jan-04-17 05:00AM  Affimed and MD Anderson Announce Clinical Immuno-Oncology Development Collaboration GlobeNewswire
Dec-13-16 04:19AM  Does Affimed NV (AFMD) Stack Up Against Its Peers? at Insider Monkey
Dec-06-16 05:00AM  Affimed Presents New Preclinical Data on Bi- and Trispecific Immune Cell Engagers at ASH GlobeNewswire -6.98%
Nov-09-16 05:00AM  Affimed to Present at the Jefferies 2016 London Healthcare Conference GlobeNewswire
Nov-08-16 05:00AM  Affimed to Present Preclinical Data on Bi- and Trispecific Immune Cell Engagers at ASH GlobeNewswire
Nov-03-16 11:01AM  Affimed NV :AFMD-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016 -9.30%
Nov-02-16 07:34AM  Affimed Reports Financial Results for Third Quarter 2016 GlobeNewswire +13.16%
07:07AM  Q3 2016 Affimed NV Earnings Release - Time Not Supplied
Oct-31-16 06:00AM  Affimed to Present at the Credit Suisse 25th Annual Healthcare Conference GlobeNewswire
Oct-26-16 05:00AM  Affimed Announces Third Quarter 2016 Financial Results and Corporate Update Conference Call GlobeNewswire
Oct-04-16 05:00AM  Affimed Presents Preclinical Data on Lead Candidate AFM13 at the Annual Meeting of the Society for Natural Immunity GlobeNewswire
Sep-22-16 05:00AM  Affimed to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology GlobeNewswire
Sep-01-16 05:00AM  Affimed to Present at Upcoming Investor Conferences GlobeNewswire
Aug-12-16 07:41AM  Affimed Therapeutics downgraded by Leerink Partners
Aug-10-16 07:30AM  Affimed Reports Financial Results for Second Quarter 2016 and Provides Corporate Update GlobeNewswire -8.54%
Aug-03-16 05:00AM  Affimed Announces Second Quarter 2016 Financial Results and Corporate Update Conference Call GlobeNewswire +9.34%
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company's product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.